drugset

drugset / Trial / NCT01250834

LY2189265 and Atorvastatin Interaction Study

NCT01250834 ↗

Phase 1 Completed 27 enrolled Eli Lilly and Company

NaSingle-groupOpen-labelTreatment

Summary

This study will assess if giving LY2189265 at the same time as atorvastatin affects how the body absorbs atorvastatin.

Timeline

Start: 2010-12
Primary completion: 2011-03
Completion: 2011-03

Publications

de la Pena A, Cui X, Geiser J, Loghin C. No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide. Clin Pharmacokinet. 2017 Nov;56(11):1415-1427. doi: 10.1007/s40262-017-0531-7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Atorvastatin	Small molecule	40 mg	Oral
Subject	Dulaglutide	Peptide	1.5 mg	Subcutaneous

Indications

No indication recorded.